Welcome to the January 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on such topics as improved 5-year survival with early use of ruxolitinib; the potential prognostic power of elevated circulating nucleosomes, and the risk of venous thromboembolism in pregnant women with essential thrombocythemia.
This month I'd like to highlight Chapter 3 of the expert video roundtable I moderated, as it emphasizes the value of obtaining bone marrow fibrosis grades to assist in determining appropriate treatment approaches in patients with primary myelofibrosis.
Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of The Journal of the Advanced Practitioner in Oncology, or JADPRO, at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus